Document 0458
 DOCN  M9480458
 TI    HTLV-II among injecting drug users in Stockholm.
 DT    9410
 AU    Krook A; Blomberg J; Department of Immunology, Microbiology, Pathology
       and Infectious; Diseases, Karolinska Institute, Huddinge University
       Hospital,; Stockholm, Sweden.
 SO    Scand J Infect Dis. 1994;26(2):129-32. Unique Identifier : AIDSLINE
       MED/94310407
 AB    134 injecting drug users (IDUs) treated at the Department of Infectious
       Diseases of Roslagstull Hospital, Stockholm, were tested for antibodies
       to human T-lymphotropic virus, types I and II, by means of 2 HTLV-I/-II
       peptide-based enzyme immunoassays (EIAs), followed by a whole-virus EIA.
       Positive EIA reactions were checked and typed by electrophoretic
       immunoblotting with native HTLV-I and recombinant HTLV-I and -II
       proteins. 10 IDUs were diagnosed as HTLV-II seropositive. All 10 were of
       Scandinavian descent. Thus, like HIV-1, HTLV-II infection has entered
       the injecting drug user population in Stockholm.
 DE    Adult  Female  Human  HTLV-II Antibodies/*BLOOD  HTLV-II
       Infections/*EPIDEMIOLOGY  Immunoenzyme Techniques  Male  Middle Age
       Prevalence  Serotyping  Substance Abuse, Intravenous/*COMPLICATIONS
       Support, Non-U.S. Gov't  Sweden/EPIDEMIOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).